Patents Examined by Meera Natarajan
  • Humanized antibodies against c-Kit
    Patent number: 11208482
    Abstract: The invention provides antibodies specifically binding to c-Kit and methods of using such antibodies in stem cell replacement and treatment of cancer.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: December 28, 2021
    Assignee: FORTY SEVEN, INC.
    Inventors: Jie Liu, Kavitha Sompalli
  • Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
    Patent number: 11174316
    Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: November 16, 2021
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: James William West, Li Mei, Stephen James Moore, Margaret T. L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
  • Readily isolated bispecific antibodies with native immunoglobulin format
    Patent number: 11168111
    Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: November 9, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Douglas MacDonald, Kara Louise Olson
  • Chimeric antigen receptor cells for treating solid tumor
    Patent number: 11161913
    Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.
    Type: Grant
    Filed: April 1, 2021
    Date of Patent: November 2, 2021
    Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
    Inventors: Lei Xiao, He Sun, Zhiyuan Cao, Wensheng Wang, Chengfei Pu, Li Mao
  • Use of anti-CD47 agents to enhance immunization
    Patent number: 11154600
    Abstract: Methods are provided for enhancing immunization strategies by manipulation, e.g. in vitro manipulation, of phagocytic antigen presenting cells. In the methods of the invention, phagocytic antigen presenting cells (phAPC) are incubated with a particulate antigen in the presence of an anti-CD47 agent in a dose and for a period of time sufficient to allow the phAPC to phagocytose the particulate antigen, which process generates a “loaded” phAPC. The loaded phAPC is contacted with a population of T cells matched for at least one major histocompatibility locus with the phAPC, where the T cells are stimulated after contacting to generate an effector response against an epitope or epitopes present on the particulate antigen.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 26, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Diane Tseng, Jens-Peter Volkmer, Kipp Andrew Weiskopf, Stephen Willingham, Irving L. Weissman
  • CD73 blocking agents
    Patent number: 11130817
    Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: September 28, 2021
    Assignees: INNATE PHARMA, CENTRE LÉON BÉRARD
    Inventors: Christophe Caux, Laurent Gauthier, Nicolas Gourdin, Christine Menetrier-Caux, Carine Paturel, Ivan Perrot
  • Multispecific antigen-binding proteins
    Patent number: 11116840
    Abstract: Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 14, 2021
    Assignee: Genentech, Inc.
    Inventors: Paul Carter, Christoph Spiess, Yiyuan Yin, Jianhui Zhou, Wendy Sandoval, Jacob Corn, Michael Dillon
  • Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
    Patent number: 11116838
    Abstract: Disclosed herein is a vaccine comprising an antigen and checkpoint inhibitor. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 14, 2021
    Assignees: The Trustees of the University of Pennsylvania, INOVIO PHARMACEUTICALS, INC.
    Inventors: David Weiner, Karuppiah Muthumani, Niranjan Sardesai
  • Anti-BCMA antibodies
    Patent number: 11111307
    Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: September 7, 2021
    Assignee: Biogen MA Inc.
    Inventors: Susan L. Kalled, Yen-Ming Hsu
  • Compositions and methods for modulating kinase activity
    Patent number: 11104741
    Abstract: The present invention features an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, therapeutic compositions comprising this antibody mimetic, and the use of the monobody to modulate Aurora A kinase for the treatment of cancer.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: August 31, 2021
    Assignee: BRANDEIS UNIVERSITY
    Inventors: Dorothee Kern, Adelajda Zorba
  • Methods of treating cancer in subjects having dysregulated lymphatic systems
    Patent number: 11104736
    Abstract: Provided herein is a method for treating cancer in a patient in need thereof, wherein said cancer has a tumor proportion score (TPS) for programmed death receptor-1 (PD-1) or programmed death-ligand-1 (PD-L1) of 50% or less and said patient is negative for lymphatic dysfunction, comprising administering a therapeutically effective amount of an antagonist for immune checkpoint inhibition.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: August 31, 2021
    Assignee: Ensemble Group Holdings
    Inventor: Michael David Kuo
  • Therapeutic compounds and methods
    Patent number: 11098101
    Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: August 24, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel Attilio Vallera, Jeffrey S. Miller
  • Therapeutic compounds and methods
    Patent number: 11098100
    Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: August 24, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel Attilio Vallera, Jeffrey S. Miller
  • Engineered IGA antibodies and methods of use
    Patent number: 11091562
    Abstract: Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: August 17, 2021
    Assignee: UMC Utrecht Holding B.V.
    Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers, Geert Jan Van Tetering
  • Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
    Patent number: 11078290
    Abstract: The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: August 3, 2021
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Sigrid Cornelis, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
    Patent number: 11078281
    Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: August 3, 2021
    Assignee: WUXI Biologies (Shanghai) Co., Ltd.
    Inventors: Zhuozhi Wang, Jing Li, Gennady Gololobov, Jianqing Xu
  • Combination therapy of immunotoxin and checkpoint inhibitor
    Patent number: 11065332
    Abstract: Regional, tumor-targeted, cytotoxic therapy, such as D2C7-immunotoxin (D2C7-IT), not only specifically target and destroy tumor cells, but in the process initiate immune events that promote an in situ vaccine effect. The antitumor effects are amplified by immune checkpoint blockade which engenders a long-term systemic immune response that effectively eliminates all tumor cells.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: July 20, 2021
    Assignees: Duke University, The Government of The United States as Represented by the Secretary of Health and Human Services, National Institutes of Health
    Inventors: Darell Bigner, Vidyalakshmi Chandramohan, Smita Nair, Matthias Gromeier, Xuhui Bao, Ira H. Pastan
  • Anti-MUC16 antibodies and uses thereof
    Patent number: 11066480
    Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: July 20, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Spriggs, Alberto Fernandez-Tejada, Dharmarao Thapi
  • Formulation for bispecific T-cell engagers (BiTEs)
    Patent number: 11052128
    Abstract: The present invention relates to stable pharmaceutical compositions which contain polypeptides having at least two antigen-binding domains and are especially suited for subcutaneous administration. The invention provides liquid compositions which minimize the formation of undesired polypeptide aggregates (dimers and/or multimers). The present invention further provides a method for minimizing the aggregation of polypeptides having antigen-binding domains in liquid compositions.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: July 6, 2021
    Assignee: AMGEN INC.
    Inventors: Carsten Olbrich, Thomas Bunte, Jonas Winter, Jörg Peters, Thomas Trill
  • Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
    Patent number: 11053318
    Abstract: The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 6, 2021
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Peter Kufer, Roman Kischel, Marion Subklewe, Christina Heitmueller